Study of lenacapavir for HIV treatment in France
Treatments studied
Part of Infections clinical trials.
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have HIV-1 (not HIV-2)
- You received your first dose of lenacapavir (by mouth or injection) between June 20, 2023 and June 30, 2024
- You took lenacapavir together with an optimized background regimen (a personalized mix of other HIV medicines)
- You did not refuse to allow your medical data to be collected and used for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with HIV who are starting or have recently started a treatment using two long-acting medications, cabotegravir and lenacapavir. It aims to see how well this combination works in real life, which could help improve care for others.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This study tests a new injectable medication called lenacapavir to prevent HIV infection. You get to choose between different HIV prevention options, and the study will see how well the injection works for you.
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Hear when a new HIV I Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.